Cytokinetics, Incorporated (CYTK)
NASDAQ · Healthcare
Cytokinetics, Incorporated EBITDA 2009–2025
Cytokinetics, Incorporated annual/quarterly ebitda history and growth rate from 2009 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Cytokinetics, Incorporated ebitda for the quarter ending March 31, 2026 was -180.2 M, a 17.55% increase year-over-year.
- Cytokinetics, Incorporated ebitda for the twelve months ending March 31, 2026 was -580.1 M, a 239.68% increase year-over-year.
- Cytokinetics, Incorporated annual ebitda for 2025 was -602.1 M, a 14.32% increase from 2024.
- Cytokinetics, Incorporated annual ebitda for 2024 was -526.7 M, a 8.76% increase from 2023.
- Cytokinetics, Incorporated annual ebitda for 2023 was -484.3 M, a 52.11% increase from 2022.
- Cytokinetics, Incorporated annual ebitda for 2022 was -318.4 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Cytokinetics, Incorporated EBITDA — FAQ
Cytokinetics, Incorporated (CYTK) ebitda over the last 17 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CYTK's ebitda history?
The chart and table above show Cytokinetics, Incorporated's ebitda by year and by quarter, including the growth rate.